Nimbus Therapeutics

Nimbus Therapeutics uses structure-based drug design enhanced by computational approaches to discover and develop breakthrough medicines. The company has demonstrated the value of its platform through significant deals, including a collaboration with Eli Lilly for a novel oral obesity treatment. Nimbus advanced NDI-219216, a WRN helicase inhibitor for MSI-high tumors, into Phase 1 clinical trials in 2025.

Structure-based drug design platform that combines computational chemistry, molecular dynamics simulations, and AI-guided optimization to design small molecule therapeutics against challenging targets. The platform has yielded multiple clinical-stage assets and high-value pharma partnerships.